medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-17-58-64medalphabet-3276Research ArticleСтатьиУправление артериальной гипертензией на фоне терапии антиангиогенными препаратами при метастатическом почечноклеточном ракеManagement of arterial hypertension during therapy with antiangiogenic drugs in metastatic renal cell carcinomaКозявинН. А.KozyavinN. A.

Козявин Никита Александрович, врач функциональной диагностики, кардиолог, онколог, терапевт, зав. консультативно-диагностическим центром

Санкт-Петербург

Kozyavin Nikita A., functional diagnostics’ physician, cardiologist, oncologist, therapist, head of Consultative and Diagnostic Centre

Saint Petersburg

kozjavin-nikita@mail.ruМурейкоЕ. А.MureykoE. A.

Мурейко Екатерина Андреевна, ординатор

Санкт-Петербург

Mureiko Ekaterina A., intern

Saint Petersburg

emureyko@mail.ruНикифоровВ. С.NikiforovV. S.

Никифоров Виктор Сергеевич, д. м. н., проф. кафедры функциональной диагностики, декан медико-биологического факультета

Санкт-Петербург

Nikiforov Viktor S., DM Sci (habil.), professor at Dept of Functional Diagnostics, dean of Faculty of Medicine and Biology

Saint Petersburg

viktor.nikiforov@szgmu.ruФГБУ «Национальный медицинский исследовательский центр онкологии имени Н. Н. Петрова» Минздрава РоссииРоссияNational Medical Research Centre of Oncology n. a. N. N. PetrovRussian FederationФГБОУ ВО «Северо-Западный государственный медицинский университет имени И. И. Мечникова» Минздрава РоссииРоссияNorth-Western State Medical University n. a. I. I. MechnikovRussian Federation202323102023017Диагностика и онкотерапия (2)5864Copyright © Козявин Н.А., Мурейко Е.А., Никифоров В.С., 20232023Козявин Н.А., Мурейко Е.А., Никифоров В.С.Kozyavin N.A., Mureyko E.A., Nikiforov V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3276

Применение антиангиогенных препаратов в монорежиме или комбинации с иммунопрепаратами при диссеминированном почечноклеточном раке позволило добиться существенных результатов в терапии метастатического процесса. Оборотной стороной эффективной терапии является развитие нежелательных явлений. Повышение артериального давления относится к наиболее частым осложнением терапии антиангиогенными препаратами с частотой встречаемости до 80 %.

The use of antiangiogenic drugs in a single mode or in combination with immunotherapy in disseminated renal cell carcinoma has made it possible to achieve significant results in the therapy of the metastatic process. The flip side of effective therapy is the development of adverse events. An increase in blood pressure is one of the most frequent complications of antiangiogenic drug therapy with a frequency of up to 80 %.

диссеминированный рак почкипочечноклеточный ракрак почкиартериальная гипертензиякардиоваскулярный рискантиангиогенные препаратыиммунотаргетная терапиятирозинкиназные ингибиторыленватинибпембролизумабdisseminated kidney cancerrenal cell carcinomakidney cancerarterial hypertensioncardiovascular riskantiangiogenic drugsimmunotargeting therapytyrosine kinase inhibitorslenvatinibpembrolizumabДанная публикация выпущена при финансовой поддержке ООО «Эйсай».This publication has been produced with the financial support of Eisai Co.ReferencesGlobal Cancer Observatory (iarc.fr).Global Cancer Observatory (iarc.fr).Под редакцией А. Д. Каприна, ВВСАОШ. Состояние онкологической помощи населению России в 2021 году.Edited by A. D. Kaprin, VSOSH. The state of oncological care to the population of Russia in 2021 (2022).Gloeckler Ries, L. A., Reichman, M. E., Lewis, D. R., Hankey, B. F. & Edwards, B. K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541–52 (2003).Gloeckler Ries, L. A., Reichman, M. E., Lewis, D. R., Hankey, B. F. & Edwards, B. K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541–52 (2003).Gloeckler Ries L. A., Reichman M. E., Lewis D. R., Hankey B. F. & Edwards B. K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541–52 (2003).Gloeckler Ries L. A., Reichman M. E., Lewis D. R., Hankey B. F. & Edwards B. K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541–52 (2003).Vaishampayan U. et al. The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database. Clin Genitourin Cancer 12, 124–129 (2014).Vaishampayan U. et al. The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database. Clin Genitourin Cancer 12, 124–129 (2014).Motzer R. et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine 384, 1289–1300 (2021).Motzer R. et al. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine 384, 1289–1300 (2021).Choueiri T. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): Extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023; 24: 228–38.Choueiri T. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): Extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023; 24: 228–38.Armstrong G. T. et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31, 3673–80 (2013).Armstrong G. T. et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 31, 3673–80 (2013).Kantor A. F., Li F. P., Janov A. J., Tarbell N. J. & Sallan S. E. Hypertension in long-term survivors of childhood renal cancers. J Clin Oncol 7, 912–5 (1989).Kantor A. F., Li F. P., Janov A. J., Tarbell N. J. & Sallan S. E. Hypertension in long-term survivors of childhood renal cancers. J Clin Oncol 7, 912–5 (1989).Fraeman K. H., Nordstrom B. L., Luo W., Landis S. H. & Shantakumar S. Incidence of new-onset hypertension in cancer patients: A retrospective cohort study. Int J Hypertens 2013, 379252 (2013).Fraeman K. H., Nordstrom B. L., Luo W., Landis S. H. & Shantakumar S. Incidence of new-onset hypertension in cancer patients: A retrospective cohort study. Int J Hypertens 2013, 379252 (2013).Petrelli F. et al. Effects of hypertension on cancer survival: A meta-analysis. Eur J Clin Invest 51, e13493 (2021).Petrelli F. et al. Effects of hypertension on cancer survival: A meta-analysis. Eur J Clin Invest 51, e13493 (2021).Whelton P. K. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71, e127–e248 (2018).Whelton P. K. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71, e127–e248 (2018).Advani A. et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proceedings of the National Academy of Sciences 104, 14448–14453 (2007).Advani A. et al. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proceedings of the National Academy of Sciences 104, 14448–14453 (2007).Eremina V. et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358, 1129–36 (2008).Eremina V. et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358, 1129–36 (2008).Lankhorst S., Kappers M. H.W., van Esch J. H.M., Danser A. H.J. & van den Meiracker A. H. Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress. Antioxid Redox Signal 20, 135–145 (2014).Lankhorst S., Kappers M. H.W., van Esch J. H.M., Danser A. H.J. & van den Meiracker A. H. Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress. Antioxid Redox Signal 20, 135–145 (2014).https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf.https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_8.5x11.pdf.Schlumberger M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372, 621–30 (2015).Schlumberger M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372, 621–30 (2015).Lyon A. R. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22, 1945–1960 (2020).Lyon A. R. et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 22, 1945–1960 (2020).Cohen J. B. & Cohen D. L. Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension. Curr Cardiol Rep 18, 112 (2016).Cohen J. B. & Cohen D. L. Integrating Out-of-Office Blood Pressure in the Diagnosis and Management of Hypertension. Curr Cardiol Rep 18, 112 (2016).Cardiovascular Events and Mortality in White Coat Hypertension. Ann Intern Med 170, 853–862 (2019).Cardiovascular Events and Mortality in White Coat Hypertension. Ann Intern Med 170, 853–862 (2019).Kronish I. M. et al. Barriers to conducting ambulatory and home blood pressure monitoring during hypertension screening in the United States. Journal of the American Society of Hypertension 11, 573–580 (2017).Kronish I. M. et al. Barriers to conducting ambulatory and home blood pressure monitoring during hypertension screening in the United States. Journal of the American Society of Hypertension 11, 573–580 (2017).McManus R.J. et al. Effect of Self-monitoring and Medication Self-titration on Systolic Blood Pressure in Hypertensive Patients at High Risk of Cardiovascular Disease: The TASMIN-SR Randomized Clinical Trial. JAMA 312, 799–808 (2014).McManus R.J. et al. Effect of Self-monitoring and Medication Self-titration on Systolic Blood Pressure in Hypertensive Patients at High Risk of Cardiovascular Disease: The TASMIN-SR Randomized Clinical Trial. JAMA 312, 799–808 (2014).Bamias A. et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer 47, 1660–1668 (2011).Bamias A. et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer 47, 1660–1668 (2011).Costa L. J.M., Varella P. C.S. & del Giglio, A. White coat effect in breast cancer patients undergoing chemotherapy. Eur J Cancer Care (Engl) 12, 372–373 (2003).Costa L. J.M., Varella P. C.S. & del Giglio, A. White coat effect in breast cancer patients undergoing chemotherapy. Eur J Cancer Care (Engl) 12, 372–373 (2003).Bottinor W. J. et al. Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition. JACC Cardiooncol 1, 14–23 (2019).Bottinor W. J. et al. Renin-Angiotensin-Aldosterone System Modulates Blood Pressure Response During Vascular Endothelial Growth Factor Receptor Inhibition. JACC Cardiooncol 1, 14–23 (2019).Li X.-Y., Sun J.-F. & Hu S.-Q. The synergy of RASBs and chemotherapy.Li X.-Y., Sun J.-F. & Hu S.-Q. The synergy of RASBs and chemotherapy.Wright J. J.T. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease. Results From the AASK Trial. JAMA 288, 2421 (2002).Wright J. J.T. Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease. Results From the AASK Trial. JAMA 288, 2421 (2002).Leenen F. H.H. et al. Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension 48, 374–384 (2006).Leenen F. H.H. et al. Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Hypertension 48, 374–384 (2006).Carey R. M. et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement from the American Heart Association. Hypertension 72, e53–e90 (2018).Carey R. M. et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement from the American Heart Association. Hypertension 72, e53–e90 (2018).2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) European Heart Journal (2022) 00, 18 https://doi.org/10.1093/eurheartj/ehac2442022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) European Heart Journal (2022) 00, 18 https://doi.org/10.1093/eurheartj/ehac244Lyon A. R. et al., Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020 Nov; 22 (11): 1945–1960. DOI: 10.1002/ejhf.1920. Epub 2020 Aug 6. PMID: 32463967; PMCID: PMC 8019326.Lyon A. R. et al., Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020 Nov; 22 (11): 1945–1960. DOI: 10.1002/ejhf.1920. Epub 2020 Aug 6. PMID: 32463967; PMCID: PMC 8019326.Инструкция по применению препарата Ленвима® (РУ: ЛП-003398 от 29.12.2015).Instructions for use of the drug Lenvima® (RU: LP-003398 dated 12/29/2015).

The authors declare that there are no conflicts of interest present.